Antibody–drug conjugates: in search of partners of choice
-
Published:2023-04
Issue:4
Volume:9
Page:339-354
-
ISSN:2405-8033
-
Container-title:Trends in Cancer
-
language:en
-
Short-container-title:Trends in Cancer
Author:
Fuentes-Antrás Jesús,
Genta Sofia,
Vijenthira Abi,
Siu Lillian L.ORCID
Subject
Cancer Research,Oncology
Reference98 articles.
1. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies;Tarantino;CA Cancer J. Clin.,2022
2. Abstract NT-090: preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer;Abrahams;Clin. Cancer Res.,2019
3. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models;Quanz;Oncotarget,2018
4. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models;Ponte;Neoplasia,2016
5. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer;Moore;Gynecol. Oncol.,2018
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献